Literature DB >> 9427882

Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis.

M Corey1, L Edwards, H Levison, M Knowles.   

Abstract

BACKGROUND: Chronic progressive lung disease is the most prominent cause of morbidity and death in patients with cystic fibrosis (CF), but severity of lung disease and rate of lung function decline are widely variable. Accurate estimates of decline have been difficult to define and compare because the timing of measurements and duration of follow-up differ in various patient groups. PATIENTS: Three hundred sixty-six patients with CF, born from 1960 to 1974, were selected from a CF database birth cohort if they had two or more measurements of pulmonary function, at least one of which was performed before the age of 10 years.
METHODS: Mixed model regression analysis provided estimates of the average rate of decline of spirometry measurements in subgroups on the basis of survival age, sex, pancreatic status, and genotype.
RESULTS: Patients who died before the age of 15 years had significantly poorer pulmonary function when first tested and a more rapid decline in pulmonary function thereafter than patients who survived beyond the age of 15 years. In the latter, functional levels at the age of 5 years were normal, but average rates of decline were significantly related to survival age. Female patients had significantly steeper decline than male patients, and those with pancreatic insufficiency had much steeper decline than those with pancreatic sufficiency. In the subset of 197 who survived to 1990 and were subsequently genotyped, rate of decline was greater in those homozygous for the delta F508 mutation, compared with those who were heterozygous for delta F508 or those, who had two other mutations. DISCUSSION: All but the most severely affected patients, who died before age 15, appear to have had normal pulmonary function when first tested in early childhood. Pancreatic sufficiency, male gender, and some non-delta F508 mutations are associated with a slower rate of pulmonary function decline. Mixed model analysis is a valuable tool for describing and comparing pulmonary function decline in groups of patients with CF.

Entities:  

Mesh:

Year:  1997        PMID: 9427882     DOI: 10.1016/s0022-3476(97)70025-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  88 in total

1.  Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint.

Authors:  M W Konstan; J S Wagener; A Yegin; S J Millar; D J Pasta; D R VanDevanter
Journal:  J Cyst Fibros       Date:  2010-06-19       Impact factor: 5.482

2.  Macrophage migration inhibitory factor enzymatic activity, lung inflammation, and cystic fibrosis.

Authors:  Huzaifa Adamali; Michelle E Armstrong; Anne Marie McLaughlin; Gordon Cooke; Edward McKone; Christine M Costello; Charles G Gallagher; Lin Leng; John A Baugh; Günter Fingerle-Rowson; Richard J Bucala; Paul McLoughlin; Seamas C Donnelly
Journal:  Am J Respir Crit Care Med       Date:  2012-05-16       Impact factor: 21.405

3.  Peak oxygen uptake and mortality in children with cystic fibrosis.

Authors:  P Pianosi; J Leblanc; A Almudevar
Journal:  Thorax       Date:  2005-01       Impact factor: 9.139

Review 4.  Advancing outcome measures for the new era of drug development in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Bonnie W Ramsey; Richard A Kronmal
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

5.  Year-to-year changes in lung function in individuals with cystic fibrosis.

Authors:  Theodore G Liou; Eric P Elkin; David J Pasta; Joan R Jacobs; Michael W Konstan; Wayne J Morgan; Jeffrey S Wagener
Journal:  J Cyst Fibros       Date:  2010-05-14       Impact factor: 5.482

Review 6.  Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.

Authors:  C Castellani; H Cuppens; M Macek; J J Cassiman; E Kerem; P Durie; E Tullis; B M Assael; C Bombieri; A Brown; T Casals; M Claustres; G R Cutting; E Dequeker; J Dodge; I Doull; P Farrell; C Ferec; E Girodon; M Johannesson; B Kerem; M Knowles; A Munck; P F Pignatti; D Radojkovic; P Rizzotti; M Schwarz; M Stuhrmann; M Tzetis; J Zielenski; J S Elborn
Journal:  J Cyst Fibros       Date:  2008-05       Impact factor: 5.482

7.  Long-term gas exchange characteristics as markers of deterioration in patients with cystic fibrosis.

Authors:  Richard Kraemer; Philipp Latzin; Isabelle Pramana; Pietro Ballinari; Sabina Gallati; Urs Frey
Journal:  Respir Res       Date:  2009-11-12

8.  Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study.

Authors:  R Mahadeva; K Webb; R C Westerbeek; N R Carroll; M E Dodd; D Bilton; D A Lomas
Journal:  BMJ       Date:  1998-06-13

9.  Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis.

Authors:  Scott D Sagel; Brandie D Wagner; Margaret M Anthony; Peggy Emmett; Edith T Zemanick
Journal:  Am J Respir Crit Care Med       Date:  2012-08-16       Impact factor: 21.405

10.  Early Childhood Risk Factors for Decreased FEV1 at Age Six to Seven Years in Young Children with Cystic Fibrosis.

Authors:  Don B Sanders; Julia Emerson; Clement L Ren; Michael S Schechter; Ronald L Gibson; Wayne Morgan; Margaret Rosenfeld
Journal:  Ann Am Thorac Soc       Date:  2015-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.